Circulating tumor DNA: a promising biomarker in stage III BRAF+ melanoma

Circulating tumor DNA: a promising biomarker in stage III BRAF+ melanoma

Saved in:

Bibliographic Details
Main Authors:	G. Roccuzzo, E. Bongiovanni, S. Marchisio, A.A. Ricci, A. Funaro, R. Senetta, S. Ribero, P. Quaglino
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EJC Skin Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772611824001083
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-world outcomes of adjuvant therapy in melanoma: an Italian referral center experience
by: G. Roccuzzo, et al.
Published: (2024-01-01)

Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma
by: Marloes Faut, et al.
Published: (2018-06-01)

The CD39/CD73/Adenosine and NAD/CD38/CD203a/CD73 Axis in Cutaneous T-Cell Lymphomas
by: Liyun Lin, et al.
Published: (2025-02-01)

Germline Non-CDKN2A Variants in Melanoma and Associated Hereditary Cancer Syndromes
by: Chiara Anna Fiasconaro, et al.
Published: (2025-06-01)

Insights on different erythroderma features in Sezary syndrome: a prospective validation study
by: G. Roccuzzo, et al.
Published: (2024-01-01)

Braf-Mutant Melanomas: Biology and Therapy
by: Elvira Pelosi, et al.
Published: (2024-12-01)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
by: Ryan J. Sullivan, et al.
Published: (2011-01-01)

Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma☆
by: G.K. In, et al.
Published: (2024-12-01)

Updates on CTCL diagnostic and therapeutic trends amidst the COVID-19 pandemic: insights from a referral center
by: G. Roccuzzo, et al.
Published: (2024-01-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
by: Yu. S. Shakh-Paronyants, et al.
Published: (2023-03-01)

Melanoma genomics – will we go beyond BRAF in clinics?
by: Justyna Mirek, et al.
Published: (2024-09-01)

Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma
by: Josué Ballesteros-Álvarez, et al.
Published: (2024-10-01)

The relationship of clinical and morphological parameters with the BRAF status of the tumor in patients with stage I skin melanoma
by: K. S. Titov, et al.
Published: (2024-09-01)

Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition
by: Danielle G. Carvalho, et al.
Published: (2025-07-01)

Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI study
by: Clara Mayo de las Casas, et al.
Published: (2025-01-01)

The role of circulating tumor DNA in melanomas of the uveal tract
by: Mohammed Zeeshan Zameer, et al.
Published: (2024-12-01)

Correction: Melanoma genomics– will we go beyond BRAF in clinics?
by: Justyna Mirek, et al.
Published: (2025-02-01)

Mutaciones de KIT, NRAS y BRAF en melanoma
by: Luz de María Díaz-Granados, et al.
Published: (2019-08-01)

Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma
by: Grant A McArthur, et al.
Published: (2025-05-01)

Circulating tumor DNA. Modern views about the possibility of use in uveal melanoma
by: A. M. Bogatyrev, et al.
Published: (2025-03-01)

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma
by: Marjon A Smit, et al.
Published: (2014-12-01)

Role of eIF6 in Modulating Response to BRAF Inhibitors and Acquired Resistance in Cutaneous Melanoma
by: G. Kyriakopoulos, et al.
Published: (2024-01-01)

Patient treatment preferences in unresectable/metastatic BRAF-mutated melanoma: a qualitative study
by: T. Amaral, et al.
Published: (2024-01-01)

Electronic patient-reported outcomes, fever management, and symptom prediction among patients with BRAF V600 mutant stage III–IV melanoma: The Kaiku Health platform
by: Peter Mohr, et al.
Published: (2024-12-01)

Circulating MicroRNAs: functional biomarkers for melanoma prognosis and treatment
by: Su Yin Lim, et al.
Published: (2025-03-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
by: Ariane Fizazi, et al.
Published: (2024-11-01)

Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
by: Bilgen Gençler, et al.
Published: (2016-01-01)

Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL)
by: Martines Gianmarco, et al.
Published: (2025-06-01)

The combination of mutations in BRAF and NRAS genes within a one tumor in patients with cutaneous melanoma
by: M. B. Aksenenko, et al.
Published: (2019-10-01)

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma
by: Felipe Ades, et al.
Published: (2012-01-01)

Predicting BRAF Mutations in Cutaneous Melanoma Patients Using Neural Network Analysis
by: Oleksandr Dudin, et al.
Published: (2024-01-01)

The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies
by: Saber Imani, et al.
Published: (2024-11-01)

Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma
by: Jiri Polivka, et al.
Published: (2024-10-01)

Vemurafenib Induces Senescent Phenotype with Increased Adhesion in BRAF Mutant A375 but not in Wild Type BRAF SK-MEL-2 Melanoma Cells
by: Aleksandra Rashidovna Esimbekova, et al.
Published: (2025-04-01)

Circulating tumor DNA for surveillance in high-risk melanoma patients: a study protocol
by: Magnús P.B. Obinah, et al.
Published: (2025-02-01)

Circulating-free DNA: A promising tool for early detection of myocardial infarction
by: Sajjad Rafiei, MD, et al.
Published: (2025-12-01)

The prognostic value of circulating in blood tumor DNA as a marker of minimal residual disease in stage I–III colorectal cancer
by: E. M. Polyanskaya, et al.
Published: (2022-06-01)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
by: Alireza Azimi, et al.
Published: (2018-03-01)

Transsulfuration Reprogramming: A Metabolic Driver of BRAF‐V600E Resistance in Melanoma
by: Juntong Chen, et al.
Published: (2025-06-01)